Normal 0 21 false false false TR X-NONE X-NONE MicrosoftInternetExplorer4 Normal 0 21 false false false TR X-NONE X-NONE MicrosoftInternetExplorer4

Normal 0 21 false false false TR X-NONE X-NONE MicrosoftInternetExplorer4

1. Çelik İ, Akalın S, Erbaş T. Serum levels of interleukin 6 and tumor necrosis factor-a in hyperthyroid patients before and after propylthiouracil treatment. European Journal of Endocrinology 1995;132:668-672.

2. Barışta İ, Tekuzman G, Güllü İ, Baltalı E, Kars A, Özışık Y, Güler N, Çelik İ, Atahan İL, Fırat D. Non-Hodgkin's lymphomas of the tonsil: A retrospective analysis of twenty-eight patients with primary tonsillary lymphoma. Tumori 1995;81:234-237.

3. Çalgüneri M, Ertenli İ, Kiraz S, Erman M, Çelik İ. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996;192:125-128.

4. Barışta İ, Çelik İ, Güllü İ, Hayran M, Akova M. Integrating the time factor into the definition of metastasis of unknown origin. Journal of the National Cancer Institute 1996;88:51.

5. Çelik İ, Kars A, Özyar E, Tekuzman G, Atahan L, Fırat D. Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma. Journal of Clinical Oncology 1996;14:1043-1044.

6. Çelik İ, Baltalı E, Barışta İ, Tekuzman G, Kansu E, Atahan L, Güngen Y, Fırat D. Solitary phalanx plasmacytoma relapse with disseminated extramedullary plasmacytomas and myeloma after short duration of remission. Anticancer Research 1996;16:959-962.

7. Ertenli İ, Haznedaroğlu İC, Kiraz S, Çelik İ, Çalgüneri M, Kirazlı Ş. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatology International 1996;16:5-8.

8. Haznedaroğlu İC, Erdem Y, Çelik İ, Sayınalp NM, Dündar SV, Çağlar Ş, Kirazlı Ş. Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients. Blood Purification 1996;14:227-233.

9. Erdem Y, Haznedaroğlu İC, Çelik İ, Yalçın AU, Yasavul Ü, Turgan Ç, Çağlar Ş. Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: Contribution of arteriovenous fistula. Nephrology Dialysis and Transplantation 1996;11:1299-1305.

10. Güllü İ, Yalçın Ş, Tekuzman G, Barışta İ, Alkış N, Çelik İ, Zengin N, Güler N, Kars A, Baltalı E, Kansu E, Fırat D. High-dose ifosfamide by infusion with mesna in advanced refractory sarcomas. Cancer Investigation 1996;14:239-242.

11. Güllü İH, Çelik İ, Tekuzman G, Altunbaş M, Güler N, Barışta İ, Alkış N, Yalçın Ş, Kars A, Baltalı E, Kansu E, Fırat D. Procarbazine, CCNU, vincristine combination in the treatment of brain tumors. Tumori 1996;82:228-231.

12. Çelik İ, Barışta İ, Fırat D. Cancer therapy during Ramadan. Journal of the National Cancer Institute 1996;88:838.

13. Haznedaroğlu İC, Erdem Y, Çelik İ, Dündar SV, Çağlar Ş, Kirazlı Ş. Haemostatic markers in amyloid vs non-amyloid uraemic patients on maintenance haemodialysis. Nephrology 1996;2:273-277.

14. Usalan C, Erdem Y, Altun B, Gürsoy M, Çelik İ, Yasavul Ü, Turgan Ç, Çağlar Ş. Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clinical Nephrology 1996;45:418.

15. Gürsoy M, Haznedaroğlu İC, Çelik İ, Sayınalp N, Özcebe Oİ, Dündar SV. Agranulocytosis, plasmacytosis, and thrombocytosis followed by a leukemoid reaction due to acute acetaminophen toxicity. The Annals of Pharmacotherapy 1996;30:762-765.

16. Haznedaroğlu İC, Özcebe O, Çelik İ, Dündar SV, Kirazlı Ş. Haemostatic markers of procoagulant imbalance in Behçet's disease. European Journal of Haematology 1996;57:107-108.

17. Kiraz S, Baltalı E, Güler N, Barışta İ, Benekli M, Çelik İ, Güllü İH, Kars A, Tekuzman G, Fırat D. Ifosfamide, mesna and epirubucin as second-line chemotherapy in advanced breast cancer. Journal of Chemotherapy 1996;8:310-314.

18. Haznedaroğlu İC, Özcebe Oİ, Özdemir O, Çelik İ, Dündar SV, Kirazlı Ş. Impaired haemostatic kinetics and endothelial function in Behçet's disease. Journal of Internal Medicine 1996;240:181-187.

19. Barışta İ, Baltalı E, Güllü İH, Güler N, Çelik İ, Saraçbaşı O, Tekuzman G, Kars A, Özışık Y, Ruacan Ş, Atahan İL, Fırat D. Factors influencing the distribution of metastases and survival in metastatic breast carcinoma. American Journal of Clinical Oncology 1996;19:569-573.

20. Yalçın Ş, Güler N, Kansu E, Ertenli İ, Güllü İ, Barışta İ, Çelik İ, Kars A, Tekuzman G, Baltalı E, Fırat D. Granulocyte-colony stimulating factor (G-CSF) administration for chemotherapy-induced neutropenia. Hematology 1996;1:155-161.

21. Çelik İ, Barışta İ, Tekuzman G, Kansu E, Kiraz S, Çalgüneri M. Behçet's disease: advantageous against development of neoplasia? Annals of the Rheumatic Diseases 1996;55:648.

22. Çelik İ, Barışta İ, Akhan S, Erdem Y, Tekuzman G. Metastatic germ cell tumor presenting with renovascular hypertension. Nephron 1996;74:486-487.

23. Çelik İ, Başçıl N, Güllü İ, Barışta İ, Çamurdanoğlu M. Difficult diagnosis in a patient with multiple osteoblastic thoracic vertebral lesions. Annals of Saudi Medicine 1996;16:590.

24. Arıcı M, Çelik İ, Tekuzman G, Özgen T. Synchronous development of renal cell carcinoma with glioblastoma multiforme. Journal of Experimental and Clinical Cancer Research 1996;15:415.

25. Erdem Y, Haznedaroğlu İC, Çelik İ, Yalçın AU, Yasavul U, Turgan Ç, Kirazlı Ş, Çağlar Ş. Coagulation and fibrinolysis in amyloid and non-amyloid hemodialysis patients: assessment of local hemostatic kinetics within arteriovenous fistulas. Clinical and Applied Thrombosis and Hemostasis 1996;2:279-284.

26. Çalgüneri M, Kiraz S, Ertenli İ, Benekli M, Karaarslan Y, Çelik İ. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet’s disease. Arthritis and Rheumatism 1996;39:2062-2065.

27. Topeli A, Barışta İ, Çelik İ, Kansu E. Timing of therapy in vasculitis-associated multiple myeloma: comment on the article by Hasegawa et al. Arthritis and Rheumatism 1997;40:395-396.

28. Çelik İ. More than IL-6 in Graves’ disease? Journal of Clinical Endocrinology and Metabolism 1997;82:1307.

29. Çalgüneri M, Kiraz S, Ertenli İ, Erman M, Karaarslan Y, Çelik İ. Characteristics of peripheral arthritis in Behçet’s disease. The New Zealand Medical Journal 1997;110:80-81.

30. Çelik İ, Başçıl N, Yalçın Ş, Güllü İH, Kars A, Barışta İ, Tekuzman G. Ifosfamide-based chemotherapy for recurrent or metastatic hemangiopericytoma. Acta Oncologica 1997;36:348.

31. Barışta İ, Çelik İ, Güllü İH, Yalçın Ş. Intrathecal chemotherapy and bone marrow. Leukemia 1997;11:1392.

32. Savaş C, Çelik İ, Benekli M, Kars A. Hyalinizing trabecular adenoma of the thyroid in a patient with hepatocellular carcinoma: Not only a pathologic, also a clinical confusion. Acta Oncologica 1997;36:436-437.

33. Çelik İ, Başçıl N, Barışta İ, Güllü İ, Tekuzman G, Fırat D. Primary central nervous system lymphoma presenting with multiple myeloma-like clinical picture. Journal of Neurology, Neurosurgery, and Psychiatry 1997;63:409-410.

34. Kiraz S, Baltalı E, Güler N, Barışta İ, Benekli M, Çelik İ, Güllü İH, Kars A, Tekuzman G, Fırat D. Ifosfamide and etoposide in previously treated patients with advanced breast cancer. Tumori 1997;83:604-607.

35. Kars A, Çelik İ, Kansu E, Tekuzman G, Özışık Y, Güler N, Barışta İ, Güllü İH, Yalçın Ş, Altundağ K, Zengin N, Türker A, Hayran M, Baltalı E, Fırat D. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma. European Journal of Haematology 1997;59:100-104.

36. Çalgüneri M, Ertenli İ, Kiraz S, Benekli M, Karaarslan Y, Çelik İ. Reply to Penicillin in the treatment of Behçet’s disase: comment on the article by Çalgüneri et al. Arthritis and Rheumatism 1997;40:1729-1730.

37. Çelik İ, Apraş Ş, Kars A, Barışta İ, Güllü İ, Güler N, Kansu E. Persistent hypercalcemia leading to acute pancreatitis in a patient with relapsed myeloma and renal failure. Nephron 1998;79:109-110.

38. Savaş C, Çelik İ, Benekli M, Güllü İH, Tekuzman G. Renal cell carcinoma presenting as solitary cervical node metastasis compressing the brachial plexus. Nephron 1998;79:107-108.

39. Haznedaroğlu İC, Çelik İ, Büyükaşık Y, Koşar A, Kirazlı Ş, Dündar SV. Haemostasis, thrombosis and endothelium in Behçet’s disease. Acta Haematologica 1998;99:236-237.

40. Yalçın Ş, Güllü İ, Barışta İ, Tekuzman G, Özışık Y, Çelik İ, Kars A. Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy. Cancer Investigation 1998;16:297-302.

41. Ertenli İ, Kiraz S, Arıcı M, Haznedaroğlu İC, Çalgüneri M, Çelik İ, Kirazlı Ş. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. Journal of Rheumatology 1998;25:1054-1058.

42. Çelik İ, Kars A, Güler N, Barışta İ, Tekuzman G, Özyılkan Ö, Hayran M, Fırat D. Phase II trial of MINE as a front-line therapeutic modality in intermediate and high grade non-Hodgkin's lymphomas. European Journal of Cancer 1998;34:759-760.

43. Yalçın Ş, Kars A, Özışık Y, Tekuzman G, Özyılkan Ö, Çelik İ, Barışta İ, Güllü İ, Güler N, Baltalı E, Fırat D. VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas. European Journal of Haematology 1998;61:261-265.

44. Kiraz S, Ertenli İ, Arıcı M, Çalgüneri M, Haznedaroğlu İ, Çelik İ, Pay S, Kirazlı Ş. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clinical and Experimental Rheumatology 1998;16:721-724.

45. Çelik İ, Erman M, Kars A, Tekuzman G. The efficacy of CCNU in non-small cell lung carcinoma presenting with cranial metastases. Journal of Experimental and Clinical Cancer Research 1998;17:375.

46. İçli F, Çelik İ, Aykan F, Üner A, Demirkazık A, Özet A, Özgüroğlu M, Taş F, Akbulut H, Fırat D. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 1998;83:2475-2480.

47. Çelik İ, Altundağ K, Erman M, Baltalı E. Cyclophosphamide associated carcinoma of the bladder in Behçet’s disease. Nephron 1999;81:239.

48. Kiraz S, Ertenli İ, Benekli M, Haznedaroğlu İC, Çalguneri M, Çelik İ, Apraş Ş, Kirazlı Ş. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999;8:737-741.

49. Ertenli İ, Kiraz S, Ertürk H, Haznedaroğlu İC, Çelik İ, Çalgüneri M, Kirazlı S. Circulating thrombopoietin in systemic sclerosis. Journal of Rheumatology 1999;26:1939-1941.

50. Barışta İ, Tekuzman G, Yalçın Ş, Güllü İ, Güler N, Özışık Y, Kars A, Çelik İ, Türker A, Altundağ K, Zengin N, Üner A, Baltalı E, Fırat D. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. Journal of Surgical Oncology 2000;73:12-16.

51. Altundağ K, Çelik İ. Human immunodeficiency virus negative Kaposi sarcoma and lymphoproliferative disorders. Cancer 2000;88:708-709.

52. Altundağ K, Çelik İ, Özışık Y. Is there a range of time for initiation of adjuvant chemotherapy in patients with malignancy? Annals of Oncology 2000;11:1209.

53. Altundağ Ö, Çelik İ, Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. The Annals of Pharmacotherapy 2001;35:641-642.

54. Erman M, Çelik İ, Tekuzman G. Fludarabine for chronic lymphocytic leukemia. New England Journal of Medicine 2001;344:1166.

55. Erman M, Çelik İ, Kars A. Cellular telephones and brain tumors. New England Journal of Medicine 2001;344:1331.

56. Ertenli İ, Kiraz S, Öztürk MA, Haznedaroğlu İC, Çelik İ, Kirazlı Ş, Çalgüneri M. Plasma fibronectin-and thrombospondin-adhesive molecules during acute attacks and attack-free periods of familial Meditarranean fever. Rheumatology International 2001;20:217-220.

57. Kiraz S, Ertenli İ, Çalgüneri M, Öztürk MA, Haznedaroğlu İC, Altun B, Erman M, Çelik İ. Interaction of nitric oxide and superoxide dismutase in Behçet's disease. Clinical and Experimental Rheumatology 2001;19(5 Suppl 24):S25-9.

58. Ertenli İ, Kiraz S, Çalgüneri M, Çelik İ, Erman M, Haznedaroğlu İC, Kirazlı Ş. Synovial fluid cytokine levels in Behçet’s disease. Clinical and Experimental Rheumatology 2001;19(5 Suppl 24):S37-41.

59. Ertenli İ, Haznedaroğlu İC, Kiraz S, Erman M, Çelik İ, Çalgüneri M, Kirazlı Ş. Changes in the concentration and distribution of TFPI in Behçet’s disease and systemic lupus erythematosus: impact on the prethrombotic state. Annals of Rheumatic Diseases 2001;60(12):1149-51.

60. Altundağ Ö, Çelik İ, Kars A. Pineal germ cell tumor metastasis via ventriculoperitoneal shunt. American Journal of Clinical Oncology 2002;25:104-5.

61. Kiraz S, Ertenli İ, Öztürk MA, Haznedaroğlu İC, Çelik İ, Çalgüneri M. Pathological haemostasis and 'prothrombotic state' in Behcet's disease. Thrombosis Research 2002;105:125-33.

62. Çelik İ, Kars A, Güç D, Tekuzman G, Ruacan Ş. Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Investigation 2002;20:333-9.

63. Engin H, Abalı H, Eman M, Karaoğlu A, Çelik İ, Güler N. Central nervous system bleeding as a first manifestation of immunothrombocytopenic purpura in Hodgkin's disease. Haematologia 2002;31:373-5.

64. Abalı H, Haznedaroğlu İC, Göker H, Çelik İ, Özatlı D, Koray Z, Çağlar M. Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology 2002;7:75-82.

65. Engin H, Çelik İ. Treatment of classical Kaposi's sarcoma with visceral involvement by weekly paclitaxel. Clinical Oncology (R Coll Radiol) 2002;14:178.

66. Öztürk MA, Barışta İ, Altındağ MK, Türker A, Yalçın Ş, Çelik İ, Güllü İH, Güler N, Özışık Y, Kars A, Kansu E, Baltalı E, Tekuzman G. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Chemotherapy 2002;48:252-258.

67. Abalı H, Çelik İ. High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel. American Journal of Clinical Oncology 2002;25:632-633.

68. Kiraz S, Ertenli İ, Öztürk MA, Haznedaroğlu İC, Çelik İ, Kirazlı Ş, Çalgüneri M. Bloodstream thrombopoietin in rheumatoid arthritis with thrombocytosis. Clinical Rheumatology 2002;21:453-456.

69. Baltalı E, Altundağ MK, Onat DA, Abbasoğlu O, Özışık Y, Güler N, Atahan L, Berberoğlu U, Altınok M, Baran I, Çelik İ, Tekuzman G. Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in local-regionally advanced breast cancer: a preliminary report. Tumori 2002;88:474-7.

70. Kiraz S, Ertenli İ, Öztürk MA, Haznedaroğlu İC, Çalgüneri M, Atalar E, Özbalkan Z, Kirazlı S, Çelik İ. Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis. Journal of Rheumatology 2003;30:313-5.

71. Ertenli İ, Kiraz S, Öztürk MA, Haznedaroğlu İC, Çelik İ, Çalgüneri M. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatology International 2003;23:49-60.

72. Karaoğlu A, Yalçın Ş, Tekuzman G, Kars A, Çelik İ, Güler N, Özışık Y, Türker A, Barışta İ, Güllü I. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors. Tumori 2003;89:141-5.

73. Kılıçkap S, Abalı H, Çelik İ. Bevacizumab, bleeding, thrombosis and warfarin. Journal of Clinical Oncology 2003;15:3542.

74. Çalgüneri M, Apraş Ş, Özbalkan Z, Ertenli İ, Kiraz S, Öztürk MA, Çelik İ. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clinical Rheumatology 2003;22:289-94.

75. Öksüzoğlu G, Bayraktar Y, Arslan S, Çelik İ, Arslan M, Sivri B, Kirazlı Ş, Kayhan B. Portal vein thrombosis in cirrhotics: related with anticardiolipin antibodies? Hepatogastroenterology 2003;50:1527-30.

76. Yalçın Ş, Öksüzoğlu B, Tekuzman G, Engin H, Çelik İ, Türker A, Barışta İ, Güllü İ, Güler N, Altundağ K, Özışık Y, Kars A. Biweekly irinotecan plus bolus 5-fluorourasil and folinic acid in patients with advanced stage colorectal cancer. Japanese Journal of Clinical Oncology 2003;33:580-583.

77. Öztürk MA, Ertenli İ, Kiraz S, Haznedaroğlu İCH, Çelik İ, Kirazlı Ş, Çalgüneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. Rheumatology International 2004;24:98-102

78. Erman M, Abalı H, Oran B, Haznedaroğlu İC, Canpınar H, Kirazlı Ş, Çelik İ. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 2004;15:1622-6.

79. Altundağ Ö, Altundağ K, Çelik İ, Türker A, Kars A. Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia. Am J Hematol 2004;75:263-4.

80. Oran B, Çelik İ, Erman M, Baltalı E, Zengin N, Demirkazık F, Tezcan S. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study. Med Oncol 2004;21:31-40.

81. Kılıçkap S, Abalı H, Aksoy S, Çelik İ. Ca 19-9 measurement as a screening: higher cost, lower survival. Journal of Gastroenterology and Hepatology 2004;19:1428.

82. Gönen C, Çelik İ, Çetinkaya YŞ, Haznedaroğlu İC. Cytarabine-induced fever complicating the clinical course of leukemia. Anticancer Drugs 2005;16:59-62.

83. Kılıçkap S, Barışta İ, Akgül E, Aytemir K, Aksöyek S, Aksoy S, Çelik İ, Kes S, Tekuzman G. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Annals of Oncology 2005;16:798-804.

84. Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Çelik İ, Bozkurt A. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005 Dec;78(6):619-26.

85. Y Solak., Aksoy S, Kilickap S, Çelik İ. Acrocyanosis as a presenting symptom of Hodgkin lymphoma. Am J Hematol 2006;81:151-152.

86. Dizdar O, Barista I, Kalyoncu U, Karadag O, Hascelik G, Cila A, Pinar A, Çelik İ, Kars A, Tekuzman G. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol 2007;82:185-191.

87. Abali H, Çelik İ. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Cancer Invest 2007;25:135-9.

88. Aksoy S, Harputluoglu H, Kilickap S, Dincer M, Dizdar O, Akdogan B, Ozen H, Erman M, Çelik İ, “Erectile dysfunction in successfully treated lymphoma patients”. Support Care Cancer 2008;16:291-297.

89. Çelik İ, Gallicchio L, Boyd K, Lam TK, Matanoski G, Tao X, Shiels M, Hammond E, Chen L, Robinson KA, Caulfield LE, Herman JG, Guallar E, Alberg AJ. Arsenic in drinking water and lung cancer: a systematic review. Environ Res 2008;10:48-55

90. Abali H, Ata A, Ozdogan M, Turhal S, Cabuk D, Seyrek E, Senol Coskun H, Arik Z, Erman M, Çelik İ. Frequency of comorbid illnesses in cancer patients in Turkey. J BUON. 2011;16:557-60.

91. Kilickap S, Barista I, Ulger S, Çelik İ, Selek U, Güllü I, Yildiz F, Kars A, Ozisik Y, Tekuzman G. Long-term complications in Hodgkin's lymphoma survivors. Tumori. 2012;98:601-6.

92. Kutluk T, Mutlu Hayran K, Kilickap S, Yuce D, Çelik İ, Erman M, Yalcin S. Increasing performance of a hospital-based cancer registry: Hacettepe University hospitals experience. J BUON. 2013;18:1088-96.

/* Style Definitions */ table.MsoNormalTable { line-height:115%; font-size:10.0pt; font-family:"Times New Roman","serif"; }

Melanom Hedefe yönelik tedaviler İmmüno-onkoloji

Lise	Anadolu Lisesi 1982
Lisans	Hacettepe Üniversitesi Tıp Fakültesi 1988
Yüksek Öğrenim	Y.Lisans / Kanser Epidemiyolojisi Prevantif Onkooji 1999 Doktora / İç Hastalıkları Tıbbi Onkoloji 1997 Uzmanlık / İç Hastalıkları 1993 Tıbbi Onkoloji 1997 Kanser Epidemiyolojisi 1999
Yurtdışı Deneyim / Eğitim	2006-2007 yılları arasında Amerika Birleşik Devletleri Johns Hopkins Üniversitesinde "Sigara ilişkili kanserler" konusunda "Visiting Professor" olarak çalışmalarda bulundu.
Yabancı Dil	İngilizce

:

: cismail@hacettepe.edu.tr

: twitter.com/http://twitter.com/kanserdenkorun